Visual loss treated with osimertinib: A case report
Dimitrios Drekolias, Scott D. Walter, Todd Alekshun
Current Problems in Cancer: Case Reports · 2022
doi:10.1016/j.cpccr.2022.100137 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Visual loss secondary to choroidal metastases is a rare initial presentation of lung cancer. Osimertinib is a third generation TKI used in treating advanced EGFR-mutation positive lung cancer. We present, to the best of our knowledge, the second published case of an EGFR-mutation positive non-small cell lung cancer (NSCLC) presenting as a choroidal metastasis and treated with osimertinib as first-line therapy.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.